Welcome to our dedicated page for Vera Therapeutics SEC filings (Ticker: VERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
At the heart of Vera Therapeutics’ 300-page disclosures lie questions any biotech investor must answer: is cash lasting through Phase 3, how are atacicept trials progressing, and when are executives selling stock? Sifting through those details in a traditional SEC browser can consume hours.
Stock Titan solves that problem. Our AI reads every Vera Therapeutics annual report 10-K, quarterly earnings report 10-Q filing, and 8-K material events, then highlights what matters: R&D expense trends, trial enrollment updates, and partnership clauses. Need real-time Vera Therapeutics Form 4 insider transactions? We alert you the moment a director files. Prefer plain English? The platform offers “Vera Therapeutics SEC filings explained simply,” turning footnotes on shelf registrations into clear bullet points.
Whether you’re tracking Vera Therapeutics insider trading Form 4 transactions, comparing segments in the Vera Therapeutics annual report 10-K simplified, or studying the Vera Therapeutics proxy statement executive compensation, every document appears seconds after it hits EDGAR. Use AI-driven keyword search to locate BK-virus antibody spend, export tables from the latest Vera Therapeutics quarterly earnings report 10-Q filing, or receive concise “understanding Vera Therapeutics SEC documents with AI” summaries for board decks. Stop scrolling through dense biotech jargon—our platform delivers Vera Therapeutics earnings report filing analysis and Vera Therapeutics 8-K material events explained so you can focus on decisions, not document hunting.
Vera Therapeutics (VERA) filed a Form 4 showing director Patrick G. Enright, through Longitude Prime Fund and Longitude Venture Partners IV, bought 250,000 Class A shares on 23–24 Jun 2025 at weighted-average prices of $20.87–$22.35, spending roughly $5.3 million. Post-transaction indirect holdings rise to 5,394,212 shares, an increase of about 4.9%. All trades were open-market purchases (code 'P'); no sales or derivatives were reported. Footnotes disclose price ranges and standard Section 16 disclaimers. The scale and direction of the trade suggest insider confidence, but the filing offers no strategic commentary.
FAQ
What is the current stock price of Vera Therapeutics (VERA)?
What is the market cap of Vera Therapeutics (VERA)?
What is the main focus of Vera Therapeutics?
How does atacicept work in treating autoimmune diseases?
What distinguishes Vera Therapeutics from other biotech companies?
What therapeutic areas are covered by Vera Therapeutics' pipeline?
How robust is the clinical trial data for atacicept?
What are the key advantages of targeting BAFF and APRIL?
How does Vera Therapeutics ensure the credibility of its research?
